According to TipRanks.com, Newman is a 4-star analyst with an average return of 5.5% and a 43.5% success rate. Newman covers the Healthcare sector, focusing on stocks such as Advanced Accelerator Applications, Hutchison China MediTech Ltd, and Synergy Pharmaceuticals Inc.
Currently, the analyst consensus on Selecta Biosciences is Strong Buy and the average price target is $30, representing a 33.3% upside.
In a report issued on October 8, Stifel Nicolaus also reiterated a Buy rating on the stock with a $32 price target.
The company has a one-year high of $28.00 and a one-year low of $10.27. Currently, Selecta Biosciences has an average volume of 116.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The firm produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation.